Xiu-Min Li, M.D., M.S.
Xiu-Min Li, M.D., M.S., was educated in both TCM and Western medicine initially in China. She was a Visiting Scientist at Stanford in Pediatric Allergy, followed by a post-doctoral fellowship in Clinical Immunology at Johns Hopkins. She then moved to the Icahn School of Medicine at Mount Sinai in New York as part of the founding team of the Jaffe Food Allergy Institute.
Dr. Li has developed many formulas for use in her private clinic for patients who suffer from skin, respiratory, and digestive system disorders, and other conditions, many of whom have conditions resistant to conventional treatment. She is a primary inventor on a number of patents of natural products for allergy and inflammation conditions and has taken on leadership roles in launching a start-up biotech company to link these interventions from the laboratory to the real world.
Dr. Li is the founder of the East-West Integrative Medicinal Symposia for Immunology and Wellness-Practice, Science and Technology, now hosted by New York Medical College. This annual symposium has attracted both national and international speakers and attendees and has attracted support from philanthropists.
Areas of Expertise
- Traditional Chinese Medicine (TCM)
Education
- M.D., Henan University of Chinese Medicine
- Postdoctoral Research Fellowship, Clinical Allergy and Immunology, Johns Hopkins University
Research
Dr. Li and her team take the knowledge of thousands of years of observation and refinement of TCM and break it down to individual molecules as visualized by individual peaks on a chromatograph. This allows the team to simplify the complexity of mixtures of plants/herbs, with their inherent variability, by isolating the active components and testing them in preclinical and clinical models of allergy and asthma. Nano-medicine technology breaks through another barrier of clinical application of some natural compounds, specifically the problem of poor bioavailability, resulting in reproducible, dependable, and clinically applicable botanical products. They also explore the mechanisms of the immune system, including bio-markers, and investigate the association of skin and gut microbiome with the TCM effect for improving skin and gut inflammatory conditions
Publications
- Xian M, Maskey AR, Kopulos D, et. al. "Advances of the exposome at individual levels and prevention in atopic dermatitis." International journal of dermatology, (), (2024) . doi: 10.1111/ijd.17559
- Maskey AR, Kopulos D, Kwan M, et. al. "Berberine Inhibits the Inflammatory Response Induced by Staphylococcus aureus Isolated from Atopic Eczema Patients via the TNF-α/Inflammation/RAGE Pathways." Cells, 13(19), (2024) . doi: 10.3390/cells13191639
- Maskey AR, Mo X, Li XM, et. al. "Preclinical Models of Atopic Dermatitis Suitable for Mechanistic and Therapeutic Investigations." Journal of inflammation research, 17(), (2024) 6955-6970. doi: 10.2147/JIR.S467327
- Musa I, Yang N, Breslin J, et. al. "Inhibition of Myeloma Cell Function by Cannabinoid-Enriched Product Associated With Regulation of Telomere and TP53." Integrative cancer therapies, 23(), (2024) 15347354241267979. doi: 10.1177/15347354241267979
- Wang ZZ, Li H, Maskey AR, et. al. "The Efficacy & Molecular Mechanisms of a Terpenoid Compound Ganoderic Acid C1 on Corticosteroid-Resistant Neutrophilic Airway Inflammation: In vivo and in vitro Validation." Journal of inflammation research, 17(), (2024) 2547-2561. doi: 10.2147/JIR.S433430
- Yang N, Srivastava K, Chen Y, et. al. "Sustained silencing peanut allergy by xanthopurpurin is associated with suppression of peripheral and bone marrow IgE-producing B cell." Frontiers in immunology, 15(), (2024) 1299484. doi: 10.3389/fimmu.2024.1299484
- Mordue DG, Hale SJ, Dennis WE, et. al. "Plasma Blood Levels of Tafenoquine following a Single Oral Dosage in BALBc Mice with Acute Babesia microti Infection That Resulted in Rapid Clearance of Microscopically Detectable Parasitemia." Pathogens (Basel, Switzerland), 12(9), (2023) . doi: 10.3390/pathogens12091113
